• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Makena (hydroxyprogesterone caproate injection) 250ml/mg

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

September 2013

Summary View

6 ADVERSE REACTIONS

6.2 Postmarketing Experience
  • added.....outcomes related to pregnancy, puerperium, and perinatal conditions and reproductive and breast disorders.

7 DRUG INTERACTIONS

  • results of an in vitro study in human hepatocytes to determine the potential of hydroxyprogesterone caproate to induce or alter the metabolic activities of CYP1A2, 2A6 and 2B6